Jones Microbiology Institute Inc

ViraQuest, Inc is a biotechnology company specializing in the production of adenoviral vectors and retains the exclusive commercial rights to RAPAd technology. Using the patented processes unique to RAPAd (U.S. Patent #6, 830, 920 ) for the generation of new constructs, we can provide the fastest turn around time of any supplier in the industry. Utilizing the RAPAd technology combined with easy subcloning steps results in production of your custom adenovirus constructs in as little as three weeks without complications of revertants. ViraQuest, Inc is your partner in research. If you don't succeed, we don't succeed. We offer an array of adenovirus services to meet your needs including new constructs, dual-expressing vectors, amplifications and isolations. We are committed to providing you with the best research materials and support in the adenovirus field. Let our vectors keep your research headed in the right direction.

NanoMedTrix LLC, located in Coralville, IA, specializes in the development and application of advanced nanoparticles for various technologies. The company is dedicated to fostering innovation through partnerships, collaborations, and internship opportunities in the field of nanotechnology. Led by President and CSO Joe Assouline, Ph.D., and Director of Manufacturing and Engineering Sean Sweeney, Ph.D., NanoMedTrix aims to push the boundaries of nanomedicine. Their commitment to research and development positions them at the forefront of the industry, driving advancements in healthcare solutions. Generated from the website

FBB Biomed, Inc., located in Coralville, IA, specializes in research-use-only blood tests aimed at enhancing the understanding of neurological health and diseases. The company focuses on leveraging innovative methodologies for classifying, detecting, and treating biological diseases, particularly in the realms of medical and pharmaceutical research. With a commitment to advancing scientific knowledge, FBB Biomed collaborates with various partners to improve clinical trial precision and gain novel insights into brain health. Their CEO, Howard Urnovitz, PhD, actively shares the development of their FBB Test, which remains a research tool and is not approved by the U.S. Food and Drug Administration for clinical use. Generated from the website